The DOI matches its Crossref record.
Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy
Abstract
OBJECTIVE: To describe a patient in whom we used adjunctive verapamil therapy was used for its P-glycoprotein inhibitory effects. CASE SUMMARY: Verapamil was added to the antiepileptic drug regimen of a 24-year-old woman with intractable epilepsy. The average time interval between hospitalizations for complex partial status doubled. The addition of verapamil greatly improved overall seizure control and subjective quality of life in this pharmacoresistant patient. DISCUSSION: The overexpression of P-glycoprotein in the central nervous system may be one mechanism of pharmacoresistance in patients with epilepsy. The calcium-channel blocker verapamil is a known inhibitor of P-glycoprotein and may function to block P-glycoprotein—modulated efflux of antiepileptic drugs in the brain, thereby raising the intracellular concentration of antiepileptic drugs and ultimately decreasing seizure burden in patients with refractory epilepsy. CONCLUSIONS: Verapamil may offer pharmacoresistant patients hope of improved seizure control due to its potential P-glycoprotein inhibitory effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
Metadata
- Authors
- Summers, M. A., Moore, J. L., & McAuley, J. W.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2004-10
- Volume
- 38
- Issue
- 10
- Pages
- 1631-1634
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2126114791
- Cited by
- 184
- References
- 0
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy. https://app.cochat.ai/papers/10.1345/aph.1e068
- The paper
- Summers, M. A., Moore, J. L., & McAuley, J. W. (2004). Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1e068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.